Arcutis Biotherapeutics, Inc. (ARQT) Stock Analysis
Recovery setup
Healthcare · Biotechnology
Hold if already holding. Not a fresh buy at $25.18, but acceptable to hold if already in. Reasons: Concentration risk — Product: ZORYVE franchise; Concentration risk — Supplier: AstraZeneca.
Arcutis Biotherapeutics is a commercial-stage dermatology company with four FDA-approved ZORYVE products targeting plaque psoriasis, seborrheic dermatitis, and atopic dermatitis in the U.S. and Canada. Revenue derives entirely from ZORYVE net product sales; the company reported... Read more
Hold if already holding. Not a fresh buy at $25.18, but acceptable to hold if already in. Reasons: Concentration risk — Product: ZORYVE franchise; Concentration risk — Supplier: AstraZeneca. Chart setup: Death cross but MACD improving, RSI 78. Mixed signals. Hold existing position. Score 6.3/10, moderate confidence.
Passes 7/8 gates (positive momentum, clean insider activity, no SEC red flags, news events none recent, earnings proximity 51d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: aggressive.
About Arcutis Biotherapeutics, Inc.
About Arcutis Biotherapeutics, Inc.
Arcutis Biotherapeutics holds four FDA-approved ZORYVE products — cream 0.3% for plaque psoriasis (July 2022), foam 0.3% for seborrheic dermatitis (December 2023) and scalp psoriasis (May 2025), cream 0.15% for atopic dermatitis (July 2024), and cream 0.05% for atopic dermatitis in children ages 2 to 5 (October 2025). The company reported a net loss of approximately $16.1 million for the year ended December 31, 2025, with an accumulated deficit of $1,138.1 million. All commercial revenue derives from the ZORYVE franchise sold in the United States and Canada.
Arcutis sells ZORYVE through a dermatologist-focused sales force in the United States and Canada. A promotion agreement with Kowa Pharmaceuticals America, Inc. to market ZORYVE through primary care and pediatric channels was mutually terminated effective January 23, 2026, and the company has since recaptured direct responsibility for that prescribing base. The company estimates an actively prescription-treated patient market of approximately 17.0 million in the U.S. across plaque psoriasis, seborrheic dermatitis, and atopic dermatitis, with roughly 3.7 million of dermatology-office patients covered by Medicare or Medicaid and roughly 4.7 million by private payers. The active pharmaceutical ingredient roflumilast is licensed exclusively from AstraZeneca AB under a 2018 agreement, with patent exclusivity for the cream formulation through 2037 and the foam formulation through 2042.
Show full overview
Arcutis's $100.0 million outstanding Loan Agreement with SLR Investment Corp. at December 31, 2025 requires the company to generate minimum net product revenue equal to 75% of projected net product revenue, tested on a trailing six-month basis each month, with the board-approved annual plan serving as the benchmark. A tranche C-1 term loan of up to $50.0 million expired March 31, 2026 and a tranche C-2 of up to $50.0 million expires June 30, 2026. If ZORYVE revenue growth fails to meet projections, the revenue covenant could trigger an event of default, potentially accelerating debt obligations due August 1, 2029.
See also: Healthcare · Biotechnology
From Arcutis Biotherapeutics, Inc.'s most recent 10-K filing, extracted June 9, 2026.
Recent developments
updated 2026-06-15Recent Developments — Arcutis Biotherapeutics, Inc.
Latest news
- NEWS Will Arcutis Biotherapeutics, Inc. (ARQT) Report Negative Earnings Next Week? What You Should Know - Yahoo Finance — Yahoo Finance negative
- NEWS Arcutis Biotherapeutics (ARQT) Expected to Announce Earnings on Wednesday - MarketBeat — MarketBeat neutral
- NEWS Arcutis Biotherapeutics EVP Masaru Matsuda sells $192k in stock - Investing.com — Investing.com negative
- NEWS Arcutis Biotherapeutics SVP CFO Latha Vairavan sells $31,661 in stock - Investing.com UK — Investing.com UK negative
- NEWS Arcutis Biotherapeutics (ARQT) officer sells 684 shares to cover RSU taxes - Stock Titan — Stock Titan negative
Generated 2026-06-15T18:11:46Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductZORYVE franchise10-K Item 1A: 'Our business is dependent on the successful commercialization of ZORYVE and the development, regulatory approval, and commercialization of our current product candidates.'
- HIGHSupplierAstraZeneca10-K Item 1: 'we executed a licensing agreement with AstraZeneca AB (AstraZeneca) for exclusive worldwide rights to roflumilast as a topical product in humans solely for dermatological indications'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker·1 ceiling hit
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $25.18, but acceptable to hold if already in. Reasons: Concentration risk — Product: ZORYVE franchise; Concentration risk — Supplier: AstraZeneca. Chart setup: Death cross but MACD improving, RSI 78. Mixed signals. Hold existing position. Target $30.12 (+19.6%), stop $23.40 (−7.6%), A.R:R 1.3:1. Score 6.3/10, moderate confidence.
Take-profit target: $30.12 (+19.7% upside). Target $30.12 (+19.6%), stop $23.40 (−7.6%), A.R:R 1.3:1. Stop-loss: $23.40.
Concentration risk — Product: ZORYVE franchise; Concentration risk — Supplier: AstraZeneca; Overbought (RSI 78).
Arcutis Biotherapeutics, Inc. trades at a P/E of N/A (forward 21.1). TrendMatrix value score: 6.8/10. Verdict: Hold.
14 analysts cover ARQT with a consensus score of 4.1/5. Average price target: $35.
What does Arcutis Biotherapeutics, Inc. do?Arcutis Biotherapeutics is a commercial-stage dermatology company with four FDA-approved ZORYVE products targeting...
Arcutis Biotherapeutics is a commercial-stage dermatology company with four FDA-approved ZORYVE products targeting plaque psoriasis, seborrheic dermatitis, and atopic dermatitis in the U.S. and Canada. Revenue derives entirely from ZORYVE net product sales; the company reported a net loss of approximately $16.1 million for 2025 against an accumulated deficit of $1,138.1 million at December 31, 2025.